Annals of Surgical Oncology

, Volume 23, Issue 12, pp 3956–3963 | Cite as

Significant Role of Palliative Gastrectomy in Selective Gastric Cancer Patients with Peritoneal Dissemination: A Propensity Score Matching Analysis

  • Run-Cong Nie
  • Shi Chen
  • Shu-Qiang Yuan
  • Xiao-Jiang Chen
  • Yong-Ming Chen
  • Bao-Yan Zhu
  • Hai-bo Qiu
  • Jun-Sheng Peng
  • Ying-Bo Chen
Gastrointestinal Oncology



The aim of this study was to explore whether palliative gastrectomy is suitable for gastric cancer patients with peritoneal metastasis, and for patients in whom the type of peritoneal metastasis should be selected to receive palliative gastrectomy.


A total of 747 patients diagnosed with gastric adenocarcinoma with peritoneal metastasis at our centers between January 2000 and April 2014 were retrospectively analyzed. After propensity score matching, the clinicopathologic characteristics and clinical outcomes of patients with peritoneal dissemination were analyzed.


After propensity score matching, the median overall survival (OS) of patients in the gastrectomy group was longer than that for patients in the non-gastrectomy group (11.87 vs. 9.27 months; p = 0.020). Patients who received first-line chemotherapy had a significantly longer median OS than those who did not (11.97 vs. 7.03 months; p < 0.001); among these patients, those undergoing more than eight periods of first-line chemotherapy benefited the most (p < 0.001). Subgroup analyses revealed that patients classified as P1 who were undergoing chemotherapy benefited from gastrectomy (p = 0.024), and patients without multisite metastasis also benefited from gastrectomy with regard to OS (p = 0.007). In the multivariate survival analysis, multisite distant metastasis was the independent poor prognostic factor (p < 0.001), while palliative gastrectomy (p = 0.006) and a period of first-line chemotherapy (p < 0.001) were good prognostic factors. Morbidity rates in the gastrectomy and non-gastrectomy groups were 10.4 and 1.0 %, respectively (p = 0.003); however, no difference in mortality was noted between the two groups (p = 0.590).


Palliative gastrectomy can prolong the survival of P1 patients without multisite distant metastasis when combined with more than five periods, and particularly more than eight periods, of first-line chemotherapy.


Gastric Cancer Overall Survival Propensity Score Gastric Cancer Patient Median Overall Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Dr. Zhiwei Zhou, Yuanfang Li, and Yupei Chen for their encouragement, support and valuable statistical help. This work was supported in part by a grant from the National Natural Science Foundation of China (81,302,144) and the Guangdong Science and Technology Department (No. 2012B0617000879).

Compliance with Ethical Standards


Run-Cong Nie, Shi Chen, Shu-Qiang Yuan, Xiao-Jiang Chen, Yong-Ming Chen, Bao-Yan Zhu, Hai-bo Qiu, Jun-Sheng Peng, and Ying-Bo Chen report no financial disclosures.

Supplementary material

10434_2016_5223_MOESM1_ESM.tif (1.7 mb)
Supplementary material 1 (TIFF 1717 kb)
10434_2016_5223_MOESM2_ESM.tif (1.6 mb)
Supplementary material 2 (TIFF 1671 kb)
10434_2016_5223_MOESM3_ESM.docx (16 kb)
Supplementary material 3 (DOCX 16 kb)


  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen S, Li YF, Feng XY, et al. Significance of palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol. 2012;106:862–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang XF, Huang CM, Lu HS, et al. Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol. 2004;10:3405–08.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hioki M, Gotohda N, Konishi M, et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg. 2010;34:555–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107.CrossRefPubMedGoogle Scholar
  9. 9.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yang K, Liu K, Zhang WH, et al. The value of palliative gastrectomy for gastric cancer patients with intraoperatively proven peritoneal seeding. Medicine (Baltimore) 2015;94:e1051.CrossRefGoogle Scholar
  14. 14.
    Xia X, Li C, Yan M, et al. Who will benefit from noncurative resection in patients with gastric cancer with single peritoneal metastasis? Am Surg. 2014;80:124–30.PubMedGoogle Scholar
  15. 15.
    He MM, Zhang DS, Wang F, et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One. 2013;8:e83921.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lasithiotakis K, Antoniou SA, Antoniou GA, et al. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. 2014;34:2079–85.PubMedGoogle Scholar
  17. 17.
    Sun J, Song Y, Wang Z, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:577.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tokunaga M, Terashima M, Tanizawa Y, et al. Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World J Surg. 2012;36:2637–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? J Surg Oncol. 2012;106:193–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Ouchi K, Sugawara T, Ono H, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol. 1998;69:41–44.CrossRefPubMedGoogle Scholar
  21. 21.
    Japanese Research Society for Gastric Cancer (1995) Japanese classification of gastric carcinoma, 1st English edn. Kanehara & Co., Ltd, Tokyo.Google Scholar
  22. 22.
    Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49:1701–20.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg. 1999;178:256–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Fujitani K, Yang HK, Kurokawa Y, et al. Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol. 2008;38:504–506.CrossRefPubMedGoogle Scholar
  26. 26.
    Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218–28.CrossRefPubMedGoogle Scholar
  27. 27.
    Dittmar Y, Rauchfuss F, Goetz M, et al. Non-curative gastric resection for patients with stage 4 gastric cancer: a single center experience and current review of literature. Langenbecks Arch Surg. 2012;397:745–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Chang YR, Han DS, Kong SH, et al. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012;19:1231–39.CrossRefPubMedGoogle Scholar
  29. 29.
    Hartgrink HH, Putter H, Klein Kranenbarg E, et al. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Medina-Franco H, Contreras-Saldivar A, Ramos-De La Medina A, et al. Surgery for stage IV gastric cancer. Am J Surg. 2004;187:543–46.CrossRefPubMedGoogle Scholar
  31. 31.
    Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy. Japan Clinical Oncology Group Study 9501. J Clin Oncol. 2004;22:2767–73.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Run-Cong Nie
    • 1
  • Shi Chen
    • 2
  • Shu-Qiang Yuan
    • 1
  • Xiao-Jiang Chen
    • 1
  • Yong-Ming Chen
    • 1
  • Bao-Yan Zhu
    • 1
  • Hai-bo Qiu
    • 1
  • Jun-Sheng Peng
    • 2
  • Ying-Bo Chen
    • 1
  1. 1.State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina
  2. 2.Department of Gastric Surgery, The 6th Affiliated HospitalSun Yat-sen UniversityGuangzhouChina

Personalised recommendations